Subject(s)
Acantholysis/pathology , Acantholysis/therapy , Dermatitis Herpetiformis/pathology , Dermatitis Herpetiformis/therapy , Acantholysis/classification , Administration, Oral , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Aged, 80 and over , Combined Modality Therapy , Dapsone/administration & dosage , Dermatitis Herpetiformis/classification , Diagnosis, Differential , Diet, Gluten-Free , Female , Humans , Treatment OutcomeABSTRACT
Pemphigus describes a group of autoimmune diseases characterized by blisters and erosions of the skin and mucous membranes, acantholysis by histology, and autoantibodies directed against epidermal cell surface components. Since the early 1970s, the following new clinical variants of pemphigus have been reported: pemphigus herpetiformis, IgA pemphigus, and paraneoplastic pemphigus. In recent years, significant data have been obtained from laboratory investigation on these rare and atypical variants, especially regarding their specific target antigens. We review these variants, their clinical presentations, histologic findings, immunopathology, target antigens, theories of pathogenesis, treatment modalities, and clinical courses.
Subject(s)
Pemphigus/classification , Acantholysis/pathology , Autoantibodies/immunology , Autoantigens/analysis , Autoimmune Diseases/classification , Blister/pathology , Dermatitis Herpetiformis/classification , Epidermis/immunology , Humans , Immunoglobulin A/immunology , Paraneoplastic Syndromes/classification , Paraneoplastic Syndromes/immunology , Pemphigus/immunology , Pemphigus/pathology , PrognosisABSTRACT
The term polymorphic pemphigoid has been used in the literature as a variant of bullous pemphigoid. But this term is imprecise and now obsolete, since patients with linear IgA dermatosis have been reported under this terminology. The patients who develop an atypical subepidermal bullous disease with clinical and histological features of both bullous pemphigoid and dermatitis herpetiformis may actually be classified into three groups: (1) vesicular variant of bullous pemphigoid; (2) linear IgA dermatosis, and (3) mixed subepidermal bullous disease.
Subject(s)
Pemphigoid, Bullous/classification , Skin Diseases, Vesiculobullous/classification , Terminology as Topic , Dermatitis Herpetiformis/classification , Humans , Immunoglobulin A/immunology , Skin Diseases, Vesiculobullous/immunologySubject(s)
Dermatitis Herpetiformis/pathology , Jejunal Diseases/pathology , Atrophy , Child , Child, Preschool , Dermatitis Herpetiformis/classification , Dermatitis Herpetiformis/immunology , Female , Humans , Immunoglobulin A/analysis , Infant , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Jejunal Diseases/immunology , Jejunum/immunology , Jejunum/pathology , Male , Skin/immunology , Skin/pathologySubject(s)
Dermatitis Herpetiformis , Adrenal Cortex Hormones/therapeutic use , Antibody Formation , Basement Membrane , Blister/complications , Child , Child, Preschool , Dermatitis Herpetiformis/classification , Dermatitis Herpetiformis/complications , Dermatitis Herpetiformis/drug therapy , Dermatitis Herpetiformis/immunology , Dermatitis Herpetiformis/pathology , Fluorescent Antibody Technique , Humans , Male , Microscopy, Electron , Sulfones/therapeutic useSubject(s)
Dermatitis Herpetiformis/diagnosis , Pemphigus/diagnosis , Adolescent , Aged , Antibodies/analysis , Blister/pathology , Dapsone/therapeutic use , Dermatitis Herpetiformis/classification , Dermatitis Herpetiformis/drug therapy , Dermatitis Herpetiformis/immunology , Dermatitis Herpetiformis/pathology , Diagnosis, Differential , Female , Fluorescent Antibody Technique , Humans , Immunoglobulin G/analysis , Pemphigus/classification , Pemphigus/drug therapy , Pemphigus/immunology , Pemphigus/pathology , Prednisone/therapeutic use , Skin/pathology , Sulfones/therapeutic useSubject(s)
Dermatitis Herpetiformis/immunology , Pregnancy Complications/immunology , Adult , Animals , Antibodies/analysis , Basement Membrane/immunology , Biopsy , Complement System Proteins/analysis , Dermatitis Herpetiformis/classification , Dermatitis Herpetiformis/drug therapy , Dermatitis Herpetiformis/pathology , Female , Fluorescent Antibody Technique , Goats/immunology , Humans , Immune Sera , Immunoglobulin G/analysis , Immunoglobulins/analysis , Iris/pathology , Pemphigus/classification , Prednisone/therapeutic use , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/pathology , Pregnancy Trimester, Second , Properdin/analysis , Pyridoxine/therapeutic use , Rabbits/immunology , Skin/immunologySubject(s)
Dermatitis Herpetiformis/pathology , Pemphigus/pathology , Skin/pathology , Acantholysis/complications , Acantholysis/pathology , Antibodies/analysis , Antibodies, Antinuclear/analysis , Biopsy , Blister/pathology , Dapsone/administration & dosage , Dapsone/therapeutic use , Dermatitis Herpetiformis/classification , Dermatitis Herpetiformis/complications , Dermatitis Herpetiformis/drug therapy , Female , Humans , Hypersensitivity, Delayed/immunology , Immunoglobulin G/analysis , Microscopy, Electron , Middle Aged , Pemphigus/immunology , Recurrence , Skin TestsSubject(s)
Dermatitis Herpetiformis/classification , Adult , Dermatitis Herpetiformis/diagnosis , Female , Humans , Male , Middle AgedABSTRACT
Tres de entre 40 enfermos del Mal de Hansen que fueran tratados con talidomida, desde noviembre de 1964 hasta la fecha, evidenciaron lesiones vesiculares. El examen histopatológico practicado en 2 de éstos mostró un cuadro semejante a la dermatitis herpertiforme. La anamnesis, la evolución y el diagnóstico diferencial permiten suponer que se trata de manifestaciones originadas en el tratamiento con talidomida.
